GE Healthcare Grants License for Biomagnetic Isolation of Nucleic Acids to Applied Biosystems

CHALFONT ST. GILES, England--(BUSINESS WIRE)--Feb. 7, 2007--GE Healthcare announced today that it has completed a license agreement with Applied Biosystems, granting Applied Biosystems access to GE Healthcare patents for the biomagnetic isolation of nucleic acids. The license, which is valid for the lifetime of the patents, grants Applied Biosystems certain rights with respect to the isolation and purification of nucleic acids using GE Healthcare's proprietary magnetic separation technology.

GE Healthcare's patented methods for magnetic separation offer significant advantages over conventional techniques for the isolation and purification of biomolecules such as DNA and RNA from laboratory and clinical samples. Benefits include greater yields of product and elimination of clogging associated with filter-based methods.

"This license recognizes the considerable value that our biomagnetic isolation technology brings to genomics researchers" said Eric Roman, General Manager, Genomic Sciences, GE Healthcare. "We are pleased to grant Applied Biosystems access to our patents in this area, which will allow them to use our proprietary magnetic separation protocols in conjunction with their MagMax(TM) range of products for nucleic acid isolation"

GE Healthcare has an active program to grant licenses for access to its patents for biomagnetic isolation. Financial terms were not disclosed.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.



Arvind Gopalratnam,

+1 262-548-2083




Europe, Middle East, Africa, Asia

Dr. Val Jones,

+44 1494 8052